The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | The eMMpower Consortium: real-world data to understand the characteristics and patterns of myeloma
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, comments on the goals of the eMMpower Consortium, stating that its aim is to create a comprehensive, curated, and validated real-world evidence database in multiple myeloma. By exploring key clinical questions, this initiative hopes to improve outcomes for patients. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The eMMpower Consortium is an effort to bring together a number of academic institutions where data is being pulled and is curated through a CRO-like process to create a very detailed real-world evidence database that looks at different types of treatment and stages at which patients are being treated. We’ve seen an explosion of research using the so-called again real-world evidence databases; some of them have huge numbers, sometimes they lack in the curation, sometimes the great detail that exists at the institutional level, but you don’t have the numbers...
The eMMpower Consortium is an effort to bring together a number of academic institutions where data is being pulled and is curated through a CRO-like process to create a very detailed real-world evidence database that looks at different types of treatment and stages at which patients are being treated. We’ve seen an explosion of research using the so-called again real-world evidence databases; some of them have huge numbers, sometimes they lack in the curation, sometimes the great detail that exists at the institutional level, but you don’t have the numbers. We have registries; we have great efforts like HealthTree, but the eMMpower Consortium is a new initiative to try to have curated, validated data from across many organizations, and in doing so, we’re hoping to explore some of the questions and get the answers for the most relevant clinical questions.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting: AbbVie, Adaptive, Amgen, Apple, BMS/Celgene, GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron, Sanofi. Scientific Advisory Board: Caris Life Sciences Board of Directors: Antengene Patent for FISH in MM.
